Cheryl Pater

A faster-acting and more potent form of tissue plasminogen activator.

B.A. Keyt, Nicholas F. Paoni, C J Refino et al. · Proceedings of the National Academy of Sciences · 1994 · 374 citations

Medicine, Pharmacokinetics, Pharmacology +12

A Variant of t-PA (T103N, KHRR 296-299 AAAA) that, by Bolus, Has Increased Potency and Decreased Systemic Activation of Plasminogen

Canio J. Refino, Nicholas F. Paoni, Bruce A. Keyt et al. · Thrombosis and Haemostasis · 1993 · 72 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

A Soluble Tissue Factor Mutant Is a Selective Anticoagulant and Antithrombotic Agent

Robert F. Kelley, Canio J. Refino, Mark P. O'Connell et al. · Blood · 1997 · 60 citations

Medicine, Hematology, Pharmacology +14

Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form.

Canio J. Refino, Nishit B. Modi, Sherron Bullens et al. · PubMed · 1998 · 27 citations

Medicine, Pharmacokinetics, Pharmacology +14

Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-peptidic, GP IIb/IIIa Receptor Antagonist following Multiple Oral Administrations of a Prodrug Form

Nishit B. Modi, Sherron Bullens, Cheryl Pater et al. · Thrombosis and Haemostasis · 1998 · 25 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +13